Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glioblastoma
is the most common and malignant primary brain tumor.
RWD domain containing 3
(
RWDD3
) has been previously reported to serve a promoting role in pituitary tumors. However, the exact role of
RWDD3
in
glioblastoma
remains unclear. Therefore, the present study aimed to investigate the expression levels of
RWDD3
in human
glioblastoma
tissues and cell lines, as well as to examine the regulatory mechanism of
RWDD3
underlying
glioblastoma
growth and metastasis. The results revealed that
RWDD3
was significantly upregulated in
glioblastoma
tissues compared with normal brain tissues, while high expression of
RWDD3
was associated with a shorter survival time of
glioblastoma
patients. The expression levels of
RWDD3
were also higher in the
glioblastoma
cell lines compared with the normal human astrocyte cell line. Subsequent to knockdown of
RWDD3
, the proliferation of
glioblastoma
U87 and U251 cells was significantly decreased, possibly due to the cell cycle arrest at G1 phase, as well as the increased cell apoptosis. Furthermore, downregulation of
RWDD3
also suppressed U87 and U251 cell invasion by inhibiting the expression levels of matrix metalloproteinase 2 (MMP2) and MMP9. Molecular mechanism investigation demonstrated that knockdown of
RWDD3
significantly downregulated the activity of the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathway. Activation of PI3K/AKT signaling prevented the suppressive effects of
RWDD3
downregulation on
glioblastoma
cell proliferation and migration, concurrent with increased protein levels of MMP2 and MMP9. In conclusion, the current study demonstrated for the first time that inhibition of
RWDD3
expression inhibited
glioblastoma
progression, at least partly, via suppressing the PI3K/AKT signaling activity, and thus
RWDD3
may be a novel potential therapeutic target for
glioblastoma
.
...
PMID:Knockdown of RWD domain containing 3 inhibits the malignant phenotypes of glioblastoma cells via inhibition of phosphoinositide 3-kinase/protein kinase B signaling. 2997 65
